Lingtak‐Neander Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lingtak‐Neander Chan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Ainsley Malone
Mt Carmel West Hospital, Columbus, Ohio
1 shared publicationBeverly Holcombe
American Society for Parenteral and Enteral Nutrition, Silver Spring, Maryland
1 shared publicationBrant K. Oelschlager
Department of Surgery, Division of General Surgery, School of Medicine, University of Washington, Seattle, Washington
1 shared publicationCharlotte H. Neilson
Graduate Program in Nutritional Sciences, School of Public Health, Seattle, WA, USA
1 shared publicationDaniel H. Teitelbaum
Department of Surgery, University of Michigan, Ann Arbor
1 shared publicationDanny D. Shen
Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington
1 shared publication
Latest Publications
- 25 April 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 25 (12) , 2321-2327
Optimization of Vitamin D Status After Roux-en-Y Gastric Bypass Surgery in Obese Patients Living in Northern Climate
Patients who undergo bariatric surgery are at risk for micronutrient deficiencies. The aims of this study were to determine the prevalence and predictors of vitamin D deficiency in obese patients residing in the northern climate, and to evaluate the effectiveness of a daily maintenance dose of vitamin D 2000 IU in preventing hypovitaminosis D within 1 year after bariatric surgery. A cohort study involving adult patients undergoing RYGB was conducted. Longitudinal changes in serum vitamin D concentrations and clinical parameters were measured and collected. Data from 134 recipients of RYGB were analyzed. Hypovitaminosis D was identified in 86 patients (64 %), and was significantly affected by seasonal change and the number of comorbidities. Follow-up data were available in 60 patients. Vitamin D sufficiency was achieved in 62.5 % of those patients with baseline vitamin D insufficiency. A dose-response relationship of vitamin D intake was observed, with the most significant increase in 25(OH)D associated with daily vitamin D intakes ≥ 2000 IU. The prevalence of hypovitaminosis D before RYGB was comparable to patients living in the non-northern climate. Daily vitamin D intake meeting at least 2000 IU is associated with greater improvement in serum vitamin D concentration.
- 25 April 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 25 (12) , 2321-2327
Optimization of Vitamin D Status After Roux-en-Y Gastric Bypass Surgery in Obese Patients Living in Northern Climate
Patients who undergo bariatric surgery are at risk for micronutrient deficiencies. The aims of this study were to determine the prevalence and predictors of vitamin D deficiency in obese patients residing in the northern climate, and to evaluate the effectiveness of a daily maintenance dose of vitamin D 2000 IU in preventing hypovitaminosis D within 1 year after bariatric surgery. A cohort study involving adult patients undergoing RYGB was conducted. Longitudinal changes in serum vitamin D concentrations and clinical parameters were measured and collected. Data from 134 recipients of RYGB were analyzed. Hypovitaminosis D was identified in 86 patients (64 %), and was significantly affected by seasonal change and the number of comorbidities. Follow-up data were available in 60 patients. Vitamin D sufficiency was achieved in 62.5 % of those patients with baseline vitamin D insufficiency. A dose-response relationship of vitamin D intake was observed, with the most significant increase in 25(OH)D associated with daily vitamin D intakes ≥ 2000 IU. The prevalence of hypovitaminosis D before RYGB was comparable to patients living in the non-northern climate. Daily vitamin D intake meeting at least 2000 IU is associated with greater improvement in serum vitamin D concentration.
- 10 March 2015
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 35 (4) , 361-369
Proximal Roux‐en‐Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P‐glycoprotein Substrates
Study Objectives: To evaluate the effect of Roux‐en‐Y gastric bypass surgery (RYGB) on the pharmacokinetics of midazolam (a CYP3A4 substrate) and digoxin (a P‐glycoprotein substrate).Design: Prospective, nonblinded, longitudinal, single‐dose pharmacokinetic study in three phases: presurgery baseline and postoperative assessments at 3 and 12 months.Patients: Twelve obese patients meeting current standards for bariatric surgery.Measurements and Main Results: At each study visit, patients received a single dose of oral digoxin and midazolam at 8 a.m. Blood samples were collected at regular intervals for 24 hours after dosing. Continuous 12‐lead electrocardiogram (EKG), heart rate, blood pressure, and respiratory rate were monitored, and pharmacokinetic parameters from the three visits were compared. The peak plasma concentration (Cmax) of midazolam increased by 66% and 71% at 3‐ and 12‐month post‐RYGB (p=0.017 and p=0.001, respectively), whereas the median time to peak concentration (Tmax) was reduced by 50%. The mean Cmax for 1′‐hydroxymidazolam increased by 87% and 80% at 3 and 12 months (p=0.001 and pmax decreased from 40 minutes at baseline to 30 and 20 minutes at 3 and 12 months, respectively. The mean AUC for digoxin, heart rate, and EKG patterns were similar across the three study phases.Conclusion: Contemporary proximal RYGB increases the rate of drug absorption without significantly changing the overall exposure to midazolam and digoxin. The Cmax of a CYP3A4 substrate with a high extraction ratio was substantially increased after RYGB.
- 10 March 2015
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 35 (4) , 361-369
Proximal Roux‐en‐Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P‐glycoprotein Substrates
Study Objectives: To evaluate the effect of Roux‐en‐Y gastric bypass surgery (RYGB) on the pharmacokinetics of midazolam (a CYP3A4 substrate) and digoxin (a P‐glycoprotein substrate).Design: Prospective, nonblinded, longitudinal, single‐dose pharmacokinetic study in three phases: presurgery baseline and postoperative assessments at 3 and 12 months.Patients: Twelve obese patients meeting current standards for bariatric surgery.Measurements and Main Results: At each study visit, patients received a single dose of oral digoxin and midazolam at 8 a.m. Blood samples were collected at regular intervals for 24 hours after dosing. Continuous 12‐lead electrocardiogram (EKG), heart rate, blood pressure, and respiratory rate were monitored, and pharmacokinetic parameters from the three visits were compared. The peak plasma concentration (Cmax) of midazolam increased by 66% and 71% at 3‐ and 12‐month post‐RYGB (p=0.017 and p=0.001, respectively), whereas the median time to peak concentration (Tmax) was reduced by 50%. The mean Cmax for 1′‐hydroxymidazolam increased by 87% and 80% at 3 and 12 months (p=0.001 and pmax decreased from 40 minutes at baseline to 30 and 20 minutes at 3 and 12 months, respectively. The mean AUC for digoxin, heart rate, and EKG patterns were similar across the three study phases.Conclusion: Contemporary proximal RYGB increases the rate of drug absorption without significantly changing the overall exposure to midazolam and digoxin. The Cmax of a CYP3A4 substrate with a high extraction ratio was substantially increased after RYGB.
- 23 October 2014
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 38 (8) , 921-923
Hangover and Hydration Therapy in the Time of Intravenous Drug Shortages
- 23 October 2014
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 38 (8) , 921-923
Hangover and Hydration Therapy in the Time of Intravenous Drug Shortages
- 20 May 2014
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 38 (6) , 656-672
The Science and Practice of Micronutrient Supplementations in Nutritional Anemia
Nutritional anemia is the most common type of anemia, affecting millions of people in all age groups worldwide. While inadequate access to food and nutrients can lead to anemia, patients with certain health status or medical conditions are also at increased risk of developing nutritional anemia. Iron, cobalamin, and folate are the most recognized micronutrients that are vital for the generation of erythrocytes. Iron deficiency is associated with insufficient production of hemoglobin. Deficiency of cobalamin or folate leads to impaired synthesis of deoxyribonucleic acid, proteins, and cell division. Recent research has demonstrated that the status of copper and zinc in the body can significantly affect iron absorption and utilization. With an increasing number of patients undergoing bariatric surgical procedures, more cases of anemia associated with copper and zinc deficiencies have also emerged. The intestinal absorption of these 5 critical micronutrients are highly regulated and mediated by specific apical transport mechanisms in the enterocytes. Health conditions that persistently alter the histology of the upper intestinal architecture, expression, or function of these substrate-specific transporters, or the normal digestion and flow of these key micronutrients, can lead to nutritional anemia. The focus of this article is to review the science of intestinal micronutrient absorption, discuss the clinical assessment of micronutrient deficiencies in relation to anemia, and suggest an effective treatment plan and monitoring strategies using an evidence-based approach.
- 20 May 2014
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 38 (6) , 656-672
The Science and Practice of Micronutrient Supplementations in Nutritional Anemia
Nutritional anemia is the most common type of anemia, affecting millions of people in all age groups worldwide. While inadequate access to food and nutrients can lead to anemia, patients with certain health status or medical conditions are also at increased risk of developing nutritional anemia. Iron, cobalamin, and folate are the most recognized micronutrients that are vital for the generation of erythrocytes. Iron deficiency is associated with insufficient production of hemoglobin. Deficiency of cobalamin or folate leads to impaired synthesis of deoxyribonucleic acid, proteins, and cell division. Recent research has demonstrated that the status of copper and zinc in the body can significantly affect iron absorption and utilization. With an increasing number of patients undergoing bariatric surgical procedures, more cases of anemia associated with copper and zinc deficiencies have also emerged. The intestinal absorption of these 5 critical micronutrients are highly regulated and mediated by specific apical transport mechanisms in the enterocytes. Health conditions that persistently alter the histology of the upper intestinal architecture, expression, or function of these substrate-specific transporters, or the normal digestion and flow of these key micronutrients, can lead to nutritional anemia. The focus of this article is to review the science of intestinal micronutrient absorption, discuss the clinical assessment of micronutrient deficiencies in relation to anemia, and suggest an effective treatment plan and monitoring strategies using an evidence-based approach.
- Open Access
- 3 March 2014
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 38 (3) , 279-280
Using Plasma Vitamin D Concentration as a Surrogate Marker to Predict Drug Response
- 3 March 2014
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 38 (3) , 279-280
Open AccessUsing Plasma Vitamin D Concentration as a Surrogate Marker to Predict Drug Response
- 1 November 2013
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 37 (6) , 702-704
Iatrogenic Malnutrition
- 1 November 2013
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 37 (6) , 702-704
Iatrogenic Malnutrition
- 14 May 2013
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 37 (4) , 450-459
Drug‐Nutrient Interactions
Drug‐nutrient interactions are defined as physical, chemical, physiologic, or pathophysiologic relationships between a drug and a nutrient. The causes of most clinically significant drug‐nutrient interactions are usually multifactorial. Failure to identify and properly manage drug‐nutrient interactions can lead to very serious consequences and have a negative impact on patient outcomes. Nevertheless, with thorough review and assessment of the patient's history and treatment regimens and a carefully executed management strategy, adverse events associated with drug‐nutrient interactions can be prevented. Based on the physiologic sequence of events after a drug or a nutrient has entered the body and the mechanism of interactions, drug‐nutrient interactions can be categorized into 4 main types. Each type of interaction can be managed using similar strategies. The existing data that guide the clinical management of most drug‐nutrient interactions are mostly anecdotal experience, uncontrolled observations, and opinions, whereas the science in understanding the mechanism of drug‐nutrient interactions remains limited. The challenge for researchers and clinicians is to increase both basic and higher level clinical research in this field to bridge the gap between the science and practice. The research should aim to establish a better understanding of the function, regulation, and substrate specificity of the nutrient‐related enzymes and transport proteins present in the gastrointestinal tract, as well as assess how the incidence and management of drug‐nutrient interactions can be affected by sex, ethnicity, environmental factors, and genetic polymorphisms. This knowledge can help us develop a true personalized medicine approach in the prevention and management of drug‐nutrient interactions.
- 14 May 2013
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 37 (4) , 450-459
Drug‐Nutrient Interactions
Drug‐nutrient interactions are defined as physical, chemical, physiologic, or pathophysiologic relationships between a drug and a nutrient. The causes of most clinically significant drug‐nutrient interactions are usually multifactorial. Failure to identify and properly manage drug‐nutrient interactions can lead to very serious consequences and have a negative impact on patient outcomes. Nevertheless, with thorough review and assessment of the patient's history and treatment regimens and a carefully executed management strategy, adverse events associated with drug‐nutrient interactions can be prevented. Based on the physiologic sequence of events after a drug or a nutrient has entered the body and the mechanism of interactions, drug‐nutrient interactions can be categorized into 4 main types. Each type of interaction can be managed using similar strategies. The existing data that guide the clinical management of most drug‐nutrient interactions are mostly anecdotal experience, uncontrolled observations, and opinions, whereas the science in understanding the mechanism of drug‐nutrient interactions remains limited. The challenge for researchers and clinicians is to increase both basic and higher level clinical research in this field to bridge the gap between the science and practice. The research should aim to establish a better understanding of the function, regulation, and substrate specificity of the nutrient‐related enzymes and transport proteins present in the gastrointestinal tract, as well as assess how the incidence and management of drug‐nutrient interactions can be affected by sex, ethnicity, environmental factors, and genetic polymorphisms. This knowledge can help us develop a true personalized medicine approach in the prevention and management of drug‐nutrient interactions.
- Open Access
- 3 February 2010
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 25 (1) , 10-12
A “Gutsy Move”
- 3 February 2010
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 25 (1) , 10-12
Open AccessA “Gutsy Move”